English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We read with interest the research letter published in Critical Care by Jouffroy et al. who suggest the utility of prehospital pulse oximetry as a red flag for early detection of silent hypoxemia in COVID-19 patients [1]. Fingertip pulse oximeters are one of the most widely used medical standard monitoring tools to assess oxygenation and respiratory function in patients. In fact, a pulse oximeter noninvasively measures arterial blood oxygen saturation (SpO2, %), and it represents an accessible tool that can be easily used by patients, physicians, and prehospital healthcare providers. However, it is important to ensure that the used pulse oximeter has a high accuracy, especially when SpO2 is lower than 90%. The accuracy criteria for the pulse oximeter equipment are provided in the International Standard ISO 80601-2-61 [2], and the U.S. Food and Drug Administration (FDA) only permits pulse oximeters that meet these criteria [3]. According to the ISO 80601-2-61, the SpO2 accuracy of a pulse oximeter should be assessed through a controlled desaturation study by comparing the SpO2 measurements with the gold standard measurements of blood arterial oxygen saturation (SaO2) obtained by a CO-oximeter. The prices for home pulse oximeters range from $20 to $80, and not all pulse oximeters are built with the same performances and the required FDA’s accuracy. Few of them have the FDA’s approval. A recent study on the accuracy of six low-cost pulse oximeters, not cleared by the FDA, has demonstrated highly inaccurate readings, even if some of them surprisingly performed likewise the expensive clinical pulse oximeters during voluntary hypoxia [4]. Some COVID-19 patients suddenly develop the condition called “silent hypoxia,” during which they still look and feel comfortable, but their SpO2 is perilously low. This happens to patients either in the hospital or at home. Low SpO2 may indicate severe COVID-19-related pneumonia, requiring a ventilator. A useful practical guidance for the correct use of pulse oximetry for monitoring patients with COVID19 at home have been very recently published [5]. SpO2 self-monitoring by patients with non-severe COVID-19, discharged from the emergency department or an outpatient testing center, is an essential way to identify patients needing to return to the hospital for a further evaluation. However, considering the largely unregulated low-cost pulse oximetry market, physicians should pay attention to incorporating SpO2 data, obtained from pulse oximeters not cleared [3] by the FDA, the European Medicine Agency or other regulatory agencies, for making medical decisions.

COVID-19: efficacy of prehospital pulse oximetry for early detection of silent hypoxemia